Food and Drug Administration

Consumer Advocates Ask Congress not to Interfere with FDA Regulation of Cannabidiol (CBD)

CFA joined Center for Science in the Public Interest, Consumer Reports, and the Public Health Institute in urging members of Congress to reject proposals to “fast track” the legalization of cannabidiol (CBD) use in dietary supplements and food products. The Food and Drug Administration (FDA) is currently evaluating the safety of CBD, and has made clear that CBD is not “generally recognized as safe” as a food additive, nor approved as dietary supplement. FDA has approved CBD as an approved drug product, and under current regulations, it may not authorize CBD for use in foods and supplements without going through notice and comment rulemaking. The letter urges Congress to give FDA the resources and authority it needs to ensure all dietary supplements and food additives are safe for consumers, and to defer to FDA’s expertise in conducting safety reviews.